Lowfloatmining1 wrote: A veteran deal maker! Hahahah piss odd with this garbage! That is a blatant LIE.
Here are several articles of Booths "reckless acquisitions using shares". You can pretend booth is a deal maker but that is complete bs.
Terry booth hired Nelson Peltz! And even he couldn't make a deal with Booth still involved. LOL
https://www.google.ca/amp/s/www.fool.ca/2018/06/14/is-aurora-cannabis-inc-tsxacb-pulling-a-valeant-pharmaceuticals-intl-inc-tsxvrx/amp/
Here's a couple paragraphs showcasing how good booth is at diluting his shareholders.
The issue with Aurora's acquisition-hungry strategy is threefold. First, ballooning the company's outstanding share count has a tendency to weigh down the value of the shares held by existing investors. For instance, over the trailing year, Aurora's market cap has risen by 67%, reflecting the added value of its purchases. However, its share price is down by 19% over this same time frame, reflecting an underperformance of 86% caused entirely by share-based dilution.
The second problem is that a ballooning outstanding share count will weigh down Aurora's ability to generate a meaningful per-share profit. Back in fiscal 2014, Aurora had just 16 million shares outstanding. As of its fiscal first quarter of 2019, it had almost 962 million. Mind you, this didn't take into account its ICC Labs acquisition or its purchase of Whistler Medical. Tack on other share-increasing tools like convertible debentures, stock options, and warrants, and Aurora could be pushing nearly 1.1 billion shares outstanding by the turn of the decade...assuming it doesn't buy another company and make matters worse.